Terms: = Prostate cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809
944 results:
1. Research of the unrecognised functions of miR-375 in prostate cancer cells.
Goztepe M; Eroglu O
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):212-218. PubMed ID: 38650131
[TBL] [Abstract] [Full Text] [Related]
2. [Explore the mechanism of astragaloside IV-PESV on proliferation, migration, and autophagy of prostate cancer cells based on the PI3K/AKT signaling pathway].
You XJ; Wen Z; Zheng QX; Li QX; Fu W; Li HS; Wang B
Zhonghua Nan Ke Xue; 2023 Dec; 29(12):963-972. PubMed ID: 38639947
[TBL] [Abstract] [Full Text] [Related]
3. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
4. The interplay between autophagy and ferroptosis presents a novel conceptual therapeutic framework for neuroendocrine prostate cancer.
Wang Y; Wu N; Li J; Liang J; Zhou D; Cao Q; Li X; Jiang N
Pharmacol Res; 2024 May; 203():107162. PubMed ID: 38554788
[TBL] [Abstract] [Full Text] [Related]
5. CPT1A mediates the succinylation of SP5 which activates transcription of PDPK1 to promote the viability and glycolysis of prostate cancer cells.
Liu S; Chen X; Zhang L; Lu B
Cancer Biol Ther; 2024 Dec; 25(1):2329372. PubMed ID: 38494680
[TBL] [Abstract] [Full Text] [Related]
6. Curcumin Enhances the Anti-cancer Efficacy of CDK4/6 Inhibitors in prostate cancer.
Zhao H; Ding R; Han J
Arch Esp Urol; 2024 Jan; 77(1):57-66. PubMed ID: 38374014
[TBL] [Abstract] [Full Text] [Related]
7. Development of certain benzylidene coumarin derivatives as anti-prostate cancer agents targeting EGFR and PI3Kβ kinases.
Elagawany M; Abdel Ghany LMA; Ibrahim TS; Alharbi AS; Abdel-Aziz MS; El-Labbad EM; Ryad N
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2311157. PubMed ID: 38348846
[TBL] [Abstract] [Full Text] [Related]
8. Exploiting epigenetic targets to overcome taxane resistance in prostate cancer.
Cevatemre B; Bulut I; Dedeoglu B; Isiklar A; Syed H; Bayram OY; Bagci-Onder T; Acilan C
Cell Death Dis; 2024 Feb; 15(2):132. PubMed ID: 38346967
[TBL] [Abstract] [Full Text] [Related]
9. Simultaneous targeting of AMPK and mtor is a novel therapeutic strategy against prostate cancer.
Zhao G; Forn-Cuní G; Scheers M; Lindenbergh PP; Yin J; van Loosen Q; Passarini L; Chen L; Snaar-Jagalska BE
Cancer Lett; 2024 Apr; 587():216657. PubMed ID: 38336289
[TBL] [Abstract] [Full Text] [Related]
10. Idebenone Exerts anti-Triple Negative Breast cancer Effects via Dual Signaling Pathways of GADD45 and AMPK.
Zhang Y; Yang F; Wu J; Huang J; Li P; Huang G
Nutr Cancer; 2024; 76(4):379-392. PubMed ID: 38332562
[TBL] [Abstract] [Full Text] [Related]
11. Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs.
Abd El-Hafeez T; Shams MY; Elshaier YAMM; Farghaly HM; Hassanien AE
Sci Rep; 2024 Jan; 14(1):2428. PubMed ID: 38287066
[TBL] [Abstract] [Full Text] [Related]
12. Leptin promotes proliferation of human undifferentiated spermatogonia by activating the PI3K/AKT/mtor pathway.
Xin S; Xiaoxuan L; Yixuan Z; Zhikang C
Am J Reprod Immunol; 2024 Jan; 91(1):e13811. PubMed ID: 38282611
[TBL] [Abstract] [Full Text] [Related]
13. Dual targeting of the androgen receptor and PI3K/AKT/mtor pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
Sugawara T; Nevedomskaya E; Heller S; Böhme A; Lesche R; von Ahsen O; Grünewald S; Nguyen HM; Corey E; Baumgart SJ; Georgi V; Pütter V; Fernández-Montalván A; Vasta JD; Robers MB; Politz O; Mumberg D; Haendler B
Mol Oncol; 2024 Mar; 18(3):726-742. PubMed ID: 38225213
[TBL] [Abstract] [Full Text] [Related]
14. Phase I Study of mtorC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mtor/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
15. VWCE modulates amino acid-dependent mtor signaling and coordinates with KICSTOR to recruit GATOR1 to the lysosomes.
Zhao T; Guan Y; Xu C; Wang D; Guan J; Liu Y
Nat Commun; 2023 Dec; 14(1):8464. PubMed ID: 38123554
[TBL] [Abstract] [Full Text] [Related]
16. Integrative analysis of transcriptomic and metabolomic profiles reveals enhanced arginine metabolism in androgen-independent prostate cancer cells.
Dai X; Shi X; Luo M; Li P; Gao Y
BMC Cancer; 2023 Dec; 23(1):1241. PubMed ID: 38104097
[TBL] [Abstract] [Full Text] [Related]
17. Sumoylation and phosphorylation of PTEN boosts and curtails autophagy respectively by influencing cell membrane localisation.
De D; Ghosh G; Karmakar P
Exp Cell Res; 2024 Jan; 434(1):113872. PubMed ID: 38072303
[TBL] [Abstract] [Full Text] [Related]
18. Synthesis and In Vitro Evaluation as Potential Anticancer and Antioxidant Agents of Diphenylamine-Pyrrolidin-2-one-Hydrazone Derivatives.
Zubrickė I; Jonuškienė I; Kantminienė K; Tumosienė I; Petrikaitė V
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069128
[TBL] [Abstract] [Full Text] [Related]
19. Tumor suppressor miR-361-3p inhibits prostate cancer progression through Gli1 and AKT/mtor signaling pathway.
Wang S; Huang X; Zhang G; Chen Z; Guan H; Zhou W
Cell Signal; 2024 Feb; 114():110998. PubMed ID: 38048859
[TBL] [Abstract] [Full Text] [Related]
20.
Giordano F; Comità S; Venneri G; Rago V; Naimo GD; De Amicis F; De Bartolo A; Tundis R; Mauro L; Panno ML
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003541
[TBL] [Abstract] [Full Text] [Related]
[Next]
